,,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,breast,4', 'breast', 'destiny-breast04', 'enhertu']
results of the destiny-breast04 were presented at #asco22 yesterday showing that enhertu reduced the risk of disease progression or death by 50% vs. chemotherapy in patients with her2-low metastatic breast cancer with hr-positive and hr-negative disease. 
We are a boutique management consulting firm that partners with biotech, IVD, and life science clients globally to develop insight-driven business solutions.